Skip to main content
. 2023 Sep 25;16(3):181–188. doi: 10.3400/avd.oa.22-00111

Table 2 Clinical outcomes of patients with PE with and without residual DVT.

PE with DVT (n=320) PE only (n=99) HR (95%CI) P value
n (%) % per patient-year (95%CI) n (%) % per patient-year (95%CI)
Recurrence or aggravation of symptomatic VTE 14 (4.4) 2.7 (1.3–4.0) 3 (3.0) 1.9 (0.0–4.1) 1.35 (0.39–4.70) 0.634
Recurrence or aggravation of symptomatic PE 9 (2.8) 1.7 (0.6–2.8) 3 (3.0) 1.9 (0.0–4.1) 0.88 (0.24–3.27) 0.854
Recurrence or aggravation of symptomatic DVT 6 (1.9) 1.1 (0.2–2.0) 1 (1.0) 0.6 (0.0–1.9) 1.75 (0.21–14.50) 0.601
Acute coronary syndrome 1 (0.3) 0.2 (0.0–0.6) 0.591
Ischemic stroke 7 (2.2) 1.3 (0.3–2.3) 1 (1.0) 0.6 (0.0–1.9) 2.15 (0.26–17.45) 0.464
Death from any cause 25 (7.8) 4.6 (2.8–6.5) 9 (9.1) 5.6 (2.0–9.3) 0.82 (0.38–1.76) 0.614
Death related to VTE 3 (0.9) 0.6 (0.0–1.2) 1 (1.0) 0.6 (0.0–1.9) 0.92 (0.10–8.84) 0.941
Death related to CVD 4 (1.3) 0.7 (0.0–1.5) 1 (1.0) 0.6 (0.0–1.9) 1.21 (0.13–10.82) 0.866
Major bleeding 9 (2.8) 2.5 (0.9–4.1) 2 (2.0) 2.0 (0.0–4.7) 1.27 (0.27–5.87) 0.761
Minor bleeding 28 (8.8) 8.1 (5.1–11.1) 3 (3.0) 3.0 (0.0–6.4) 4.09 (0.97–17.19) 0.037

A P value of <0.05 was considered statistically significant. CI: confidence interval; CVD: cardiovascular disease; DVT: deep vein thrombosis; HR: hazard ratio; PE: pulmonary thromboembolism; VTE: venous thromboembolism